使用病毒体剂型甲型肝炎疫苗加强免疫后，成功的记忆反应延迟长达11年。
Successful memory response following a booster dose with a virosome-formulated hepatitis a vaccine delayed up to 11 years.
作者信息
Hatz Christoph, van der Ploeg Robert, Beck Bernhard R, Frösner Gert, Hunt Marjory, Herzog Christian
机构信息
Medical Department Swiss Tropical and Public Health Institute, P.O. Box, CH-4002 Basel, Switzerland.
出版信息
Clin Vaccine Immunol. 2011 May;18(5):885-7. doi: 10.1128/CVI.00358-10. Epub 2011 Mar 16.
Abstract
Boosting adult travelers with the virosome-formulated, aluminum-free hepatitis A vaccine Epaxal up to 128 months after a single primary dose confers full protection against hepatitis A, even in travelers aged 50 years and above. Delaying the booster dose did not influence the immune memory response to Epaxal.
摘要
对于单次初免剂量后长达128个月的成年旅行者，使用无铝、病毒体配方的甲型肝炎疫苗Epaxal进行加强免疫，即使对于50岁及以上的旅行者，也能提供针对甲型肝炎的全面保护。推迟加强免疫剂量不会影响对Epaxal的免疫记忆反应。
相似文献
1
Successful memory response following a booster dose with a virosome-formulated hepatitis a vaccine delayed up to 11 years.使用病毒体剂型甲型肝炎疫苗加强免疫后，成功的记忆反应延迟长达11年。
Clin Vaccine Immunol. 2011 May;18(5):885-7. doi: 10.1128/CVI.00358-10. Epub 2011 Mar 16.
2
Successful booster antibody response up to 54 months after single primary vaccination with virosome-formulated, aluminum-free hepatitis A vaccine.使用无铝的病毒体配方甲型肝炎疫苗进行单次初次接种后，长达54个月的加强抗体反应成功。
Clin Infect Dis. 2003 Nov 1;37(9):e126-8. doi: 10.1086/378890. Epub 2003 Sep 30.
3
Immunogenicity and tolerability of a paediatric presentation of a virosomal hepatitis A vaccine in Chilean children aged 1-16 years.智利 1-16 岁儿童使用含甲型肝炎病毒疫苗的小儿剂型的免疫原性和耐受性。
Vaccine. 2011 Nov 8;29(48):8855-62. doi: 10.1016/j.vaccine.2011.09.095. Epub 2011 Oct 6.
4
Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial.12至15月龄儿童同时接种病毒体佐剂甲型肝炎疫苗与常规儿童疫苗：一项随机对照试验。
Pediatr Infect Dis J. 2007 Sep;26(9):787-93. doi: 10.1097/INF.0b013e318060acbd.
5
Long-term Serologic Follow-up of Children Vaccinated with a Pediatric Formulation of Virosomal Hepatitis A Vaccine Administered With Routine Childhood Vaccines at 12-15 Months of Age.对12至15月龄儿童接种含甲型肝炎病毒体疫苗儿科剂型并同时接种常规儿童疫苗后的长期血清学随访。
Pediatr Infect Dis J. 2016 Jul;35(7):e220-8. doi: 10.1097/INF.0000000000001176.
6
Rapid antibody response after vaccination with a virosomal hepatitis a vaccine.接种病毒体甲型肝炎疫苗后的快速抗体反应。
Infection. 2004 Jun;32(3):149-52. doi: 10.1007/s15010-004-3147-4.
7
Long-term antibody persistence in children after vaccination with the pediatric formulation of an aluminum-free virosomal hepatitis A vaccine.使用不含铝的病毒体甲型肝炎疫苗儿科制剂对儿童进行疫苗接种后抗体的长期持久性。
Pediatr Infect Dis J. 2015 Apr;34(4):e85-91. doi: 10.1097/INF.0000000000000616.
8
Predicted 30-year protection after vaccination with an aluminum-free virosomal hepatitis A vaccine.无铝佐剂小核糖核酸疫苗免疫后 30 年的预测保护效果。
J Med Virol. 2010 Oct;82(10):1629-34. doi: 10.1002/jmv.21883.
9
Immunogenicity of booster vaccination with a virosomal hepatitis A vaccine after primary immunization with an aluminum-adsorbed hepatitis A vaccine.在接种吸附铝的甲型肝炎疫苗进行初次免疫后，使用病毒体甲型肝炎疫苗进行加强免疫的免疫原性。
J Travel Med. 2004 Jul-Aug;11(4):201-6. doi: 10.2310/7060.2004.19002.
10
Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly.一种病毒体甲型肝炎疫苗（Epaxal）在老年人中的免疫原性和安全性。
J Travel Med. 2006 Mar-Apr;13(2):78-83. doi: 10.1111/j.1708-8305.2006.00001.x.
引用本文的文献
1
Virosome: An engineered virus for vaccine delivery.病毒体：一种用于疫苗递送的工程病毒。
Saudi Pharm J. 2023 May;31(5):752-764. doi: 10.1016/j.jsps.2023.03.016. Epub 2023 Mar 31.
2
Emerging Trends in Lipid-Based Vaccine Delivery: A Special Focus on Developmental Strategies, Fabrication Methods, and Applications.基于脂质的疫苗递送的新兴趋势：特别关注开发策略、制备方法及应用
Vaccines (Basel). 2023 Mar 15;11(3):661. doi: 10.3390/vaccines11030661.
3
Immunomodulatory nanosystems: An emerging strategy to combat viral infections.免疫调节纳米系统：一种对抗病毒感染的新兴策略。
Biomater Biosyst. 2023 Jan 30;9:100073. doi: 10.1016/j.bbiosy.2023.100073. eCollection 2023 Mar.
4
Virosome-based nanovaccines; a promising bioinspiration and biomimetic approach for preventing viral diseases: A review.基于病毒体的纳米疫苗；预防病毒病的有前途的仿生学和仿生方法：综述。
Int J Biol Macromol. 2021 Jul 1;182:648-658. doi: 10.1016/j.ijbiomac.2021.04.005. Epub 2021 Apr 16.
5
Hepatitis A vaccination and its immunological and epidemiological long-term effects - a review of the evidence.甲型肝炎疫苗接种及其免疫和流行病学的长期效果——证据综述。
Hum Vaccin Immunother. 2021 May 4;17(5):1496-1519. doi: 10.1080/21645515.2020.1819742. Epub 2020 Dec 16.
6
Homelessness and Hepatitis A-San Diego County, 2016-2018.2016-2018 年，圣地亚哥县的无家可归者与甲型肝炎
Clin Infect Dis. 2020 Jun 24;71(1):14-21. doi: 10.1093/cid/ciz788.
7
Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines - A systematic review.单价灭活甲型肝炎疫苗全民大规模接种的影响——一项系统评价
Hum Vaccin Immunother. 2017 Mar 4;13(3):724-736. doi: 10.1080/21645515.2016.1242539. Epub 2016 Oct 27.
8
Comparison of immune persistence among inactivated and live attenuated hepatitis a vaccines 2 years after a single dose.单剂量接种甲型肝炎灭活疫苗和减毒活疫苗2年后免疫持久性的比较
Hum Vaccin Immunother. 2016 Sep;12(9):2322-6. doi: 10.1080/21645515.2015.1134069. Epub 2016 Aug 5.
9
The impact of assumptions regarding vaccine-induced immunity on the public health and cost-effectiveness of hepatitis A vaccination: Is one dose sufficient?关于疫苗诱导免疫的假设对甲型肝炎疫苗接种的公共卫生和成本效益的影响：一剂是否足够？
Hum Vaccin Immunother. 2016 Nov;12(11):2765-2771. doi: 10.1080/21645515.2016.1203495. Epub 2016 Jul 18.
10
Seropositivity among Korean Young Adults Approximately 2 Years after a Single-Dose Vaccination against Hepatitis A Virus.甲型肝炎病毒单剂量疫苗接种约两年后韩国年轻人中的血清阳性率
PLoS One. 2015 Nov 5;10(11):e0142297. doi: 10.1371/journal.pone.0142297. eCollection 2015.
本文引用的文献
1
Predicted 30-year protection after vaccination with an aluminum-free virosomal hepatitis A vaccine.无铝佐剂小核糖核酸疫苗免疫后 30 年的预测保护效果。
J Med Virol. 2010 Oct;82(10):1629-34. doi: 10.1002/jmv.21883.
2
Hepatitis A risk in travelers.旅行者中的甲型肝炎风险。
J Travel Med. 2009 Jul-Aug;16(4):233-8. doi: 10.1111/j.1708-8305.2009.00307.x.
3
Epaxal: a virosomal vaccine to prevent hepatitis A infection.依帕沙尔：一种预防甲型肝炎感染的病毒体疫苗。
Expert Rev Vaccines. 2008 Oct;7(8):1141-50. doi: 10.1586/14760584.7.8.1141.
4
Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP).通过主动或被动免疫预防甲型肝炎：免疫实践咨询委员会（ACIP）的建议。
MMWR Recomm Rep. 2006 May 19;55(RR-7):1-23.
5
Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly.一种病毒体甲型肝炎疫苗（Epaxal）在老年人中的免疫原性和安全性。
J Travel Med. 2006 Mar-Apr;13(2):78-83. doi: 10.1111/j.1708-8305.2006.00001.x.
6
Excellent booster response 4 to 8 years after a single primary dose of an inactivated hepatitis A vaccine.在单剂灭活甲肝疫苗初次接种4至8年后出现优异的加强免疫反应。
J Travel Med. 2004 Mar-Apr;11(2):120-1. doi: 10.2310/7060.2004.17079.
7
Successful booster antibody response up to 54 months after single primary vaccination with virosome-formulated, aluminum-free hepatitis A vaccine.使用无铝的病毒体配方甲型肝炎疫苗进行单次初次接种后，长达54个月的加强抗体反应成功。
Clin Infect Dis. 2003 Nov 1;37(9):e126-8. doi: 10.1086/378890. Epub 2003 Sep 30.
8
Inactivated hepatitis A vaccine booster given >/=24 months after the primary dose.在首剂接种至少24个月后接种甲型肝炎灭活疫苗加强针。
Vaccine. 2000 Oct 15;19(4-5):399-402. doi: 10.1016/s0264-410x(00)00188-2.
9
Hepatitis A virus-specific humoral and cellular immune responses following immunization with a formalin-inactivated hepatitis A vaccine.用福尔马林灭活甲肝疫苗免疫后甲肝病毒特异性体液免疫和细胞免疫反应
Vaccine. 1999 Dec 10;18(9-10):892-8. doi: 10.1016/s0264-410x(99)00342-4.
10
The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults.年龄和体重对健康成年人中甲醛灭活、铝佐剂甲型肝炎疫苗反应的影响。
Vaccine. 1997 Jul;15(10):1157-61. doi: 10.1016/s0264-410x(96)00310-6.
Zotero 插件